USMLE Step1 SuperMemo KQB Pharmacology

Go back to the Database List

---

KQB Pharmacology section.001-050

C: Pharmacology
Q: The use of ..., a prokinetic agent, that stimulate GI tract, is absolutly containdicated in Pt with bowel obstuction.
A: Metoclopramide
3: GI
4: Qbank 001-050.01

<!--T:2-->
C: Pharmacology
Q: ACE inhibitors are proven to delay progression of CHF by protecting the ventricles from ...
A: remodeling
3: CardioVascular
4: Qbank 001-050.03

<!--T:3-->
C: Pharmacology
Q: Ammonium Cloride ... the urine increase toxicity with ..., used for threatment of metabolic ... and ... states
A: -acidify urine//-salycilate//Rx:-metabolic alcalosis and hypoCl 
3: Drug Interaction
4: Qbank 001-050.05

<!--T:4-->
C: Pharmacology
Q: Gradual return to conciusness with cessation of seizure activity is __
A: Tonic-Clonic seizures
3: Difference btw TonicClonic and Status Epilepticus
4: Qbank 001-050.14

<!--T:5-->
C: Pharmacology
Q: No return to conciusness and no cessation of seizure activity is __
A: Status Epilepticus (med emergency)
3: Difference btw TonicClonic and Status Epilepticus
4: Qbank 001-050.14

<!--T:6-->
C: Pharmacology
Q: Rx of Status Epilepticus, wich is medical emergency
A: -Diazepam (benzo)//-Phenytoin for long term seizure control
3: Medical Emergency
4: Qbank 001-050.14

<!--T:7-->
C: Pharmacology
Q: Rx for Klebsiella Pneumonie is
A: -Cefotaxime//-Ceftriaxone//-Ceftazidomide//(3rd generation of cefalosporin)
3: Rx for Pneumonia
4: Qbank 001-050.16

<!--T:8-->
C: Pharmacology
Q: Gentamicin used as addition to Vancomicin or Penicillin in the treatment of [2]
A: -Pseudomonas//-Enterococcus
3: Rx for Pneumonia
4: Qbank 001-050.16

<!--T:9-->
C: Pharmacology
Q: Maximum effect that can be produced by a drug, regardless of dose is ...
A: Efficacy
3: Terminology
4: Qbank 001-050.17

<!--T:10-->
C: Pharmacology
Q: The dose of concentration required to produce 50% of the drug maximum effect is ...
A: Potency
3: Terminology
4: Qbank 001-050.17

<!--T:11-->
C: Pharmacology
Q: The dose that causes death in 50% of population is 
A: LD50
3: Terminology
4: Qbank 001-050.17

<!--T:12-->
C: Pharmacology
Q: NON Sulfa oral hypoglycemic agent for NIDDM Type 2
A: Metformin (biguanide)
3: Rx for Diabetis
4: Qbank 001-050.19

<!--T:13-->
C: Pharmacology
Q: HyperKalemia can be caused by ..., due to ... ...
A: -Succinilcholine//-Prolonged depolarization
3: Misc
4: Qbank 001-050.21

<!--T:14-->
C: Pharmacology
Q: Coffeine inhibit ... => cAMP continius to activate ... => increase glycogen and triglyceride breakdown
A: -Phoshodiesterase (PDE)//-Protein Kinase A
3: Mechanism of Action
4: Qbank 001-050.28

<!--T:15-->
C: Pharmacology
Q: ... decrease hepatic glucose output and improves perepheral insulin utilization
A: Pioglitazone
3: Rx for Diabetis
4: Qbank 001-050.29

<!--T:16-->
C: Pharmacology
Q: ... can cause Lactic Acidosis
A: Metformin (or nephrotoxic drugs)
3: Misc
4: Qbank 001-050.31

<!--T:17-->
C: Pharmacology
Q: Amoxapine is a ..., can cause ... ... syndrome
A: -TCA//-Neuroleptic Malignan Syndrome
3: Misc
4: Qbank 001-050.33

<!--T:18-->
C: Pharmacology
Q: Severe idiosyncratic hepatocellular injury can follow ... administration.
A: Troglitazone
3: Rx for Diabetis
4: Qbank 001-050.48

<!--T:19-->
C: Pharmacology
Q: Direct antispasmodic effect and inhibit the muscarinic action of Ach on smooth muscle, used in bladder instability (urinary urgency and incontinence)
A: Oxybutynin
3: Misc
4: Qbank 001-050.49

<!--T:20-->
C: Pharmacology
Q: activation of ... ... receptor produce stronges Ca++ flux
A: -Alpha.1 adrenergic receptor
3: Misc
4: Qbank 001-050.50

/KQB Pharmacology section.051-100

C: Pharmacology
Q: ... - aPTT//activated Partial Tromboplasmin Time
A: Heparin
3: Anticoagulants
4: Qbank 051-100.4

<!--T:22-->
C: Pharmacology
Q: Bleeding time - measure of ...
A: Platelet fx
3: Anticoagulants
4: Qbank 051-100.4

<!--T:23-->
C: Pharmacology
Q: Internaional Normalized Ratio (INR) and //Protrombin Time (PT) used to monitor ... (...)
A: coumarin (warfarin)
3: Anticoagulants
4: Qbank 051-100.4

<!--T:24-->
C: Pharmacology
Q: ... is a selective estrogen agonist and favorable effect on LDL and cholesterol
A: Raloxifene
3: Endocrin
4: Qbank 051-100.5

<!--T:25-->
C: Pharmacology
Q: Tamoxifen is ... ... ...
A: competitive estogen antagonist
3: Endocrin
4: Qbank 051-100.5

<!--T:26-->
C: Pharmacology
Q: Valproic acid DOC for ... syndrome, because it very effective and it is ...
A: -myoclonic synd//-nonsedating
3: Seizures
4: Qbank 051-100.8

<!--T:27-->
C: Pharmacology
Q: Celecoxib ... drug ... inhibitor
A: -sulfa//-COX2
3: Antiinflam
4: Qbank 051-100.9

<!--T:28-->
C: Pharmacology
Q: Ketorolac - ...
A: NSAID
3: Antiinflam
4: Qbank 051-100.9

<!--T:29-->
C: Pharmacology
Q: Tramadol - ... ... stimulator (analgetic and resp depression) and inhibit uptake of ... and ...
A: -mu opiate//-serotonin and NE
3: CNS
4: Qbank 051-100.9

<!--T:30-->
C: Pharmacology
Q: Metoclopramid is a ... agent indicated for the treatment of ... and ... ...
A: -prokinetic//-GERD and diabetic gastroparesis
3: Misc
4: Qbank 051-100.10

<!--T:31-->
C: Pharmacology
Q: Metoclopramid antogonize ... receptors, leading to ...
A: -dopamin//-Parkinson
3: Misc
4: Qbank 051-100.10

<!--T:32-->
C: Pharmacology
Q: Cisapride ... agent for the treatment of ..., associated with ... ... and ... ...
A: -prokinetic//-GERD//-arrhythmias, diarrhea and abdominal cramping
3: Misc
4: Qbank 051-100.10

<!--T:33-->
C: Pharmacology
Q: Sucralfate - ...
A: constipation
3: Adverse Effects
4: Qbank 051-100.10

<!--T:34-->
C: Pharmacology
Q: Meperidin narcotic with ... propertis (...), for ...
A: -antimuscarinic (no spasm)//-gallstones
3: Misc
4: Qbank 051-100.11

<!--T:35-->
C: Pharmacology
Q: Obsessive-Compulsive Disorder threat with ... (...), ... (...)
A: -TCA (clomipramine)//-SSRI (fluoxetine)
3: CNS
4: Qbank 051-100.12

<!--T:36-->
C: Pharmacology
Q: ... increase appetite
A: Megistrol
3: Misc
4: Qbank 051-100.18

<!--T:37-->
C: Pharmacology
Q: Sustained eyes deviation is a form of dystonia called ... ...
A: oculogyric crisis
3: CNS
4: Qbank 051-100.20

<!--T:38-->
C: Pharmacology
Q: oculogyric crisis after ...
A: haloperidol
3: CNS
4: Qbank 051-100.20

<!--T:39-->
C: Pharmacology
Q: oculogyric crisis preventable with ... (...), ... (...), ...
A: -antihystamines (diphenhydramine),//-antiholinergic (benzotropine),//-diazepam
3: CNS
4: Qbank 051-100.20

<!--T:40-->
C: Pharmacology
Q: ... - ... ... - feeling of restlessness, frequent stereotyped movement, inability to sit still.
A: Akathisia - extrapyramidal synd
3: CNS
4: Qbank 051-100.20

<!--T:41-->
C: Pharmacology
Q: ... and ... save in pregnancy to treat HTN
A: Methyldopa and Hydralazine
3: Misc
4: Qbank 051-100.21

<!--T:42-->
C: Pharmacology
Q: ... inhibit warfarin metabolism
A: Norfloxacin
3: Misc
4: Qbank 051-100.23

<!--T:43-->
C: Pharmacology
Q: ... ... will treat arthralgias and skin rash in serum sickness
A: Oral Prednisone
3: Misc
4: Qbank 051-100.24

<!--T:44-->
C: Pharmacology
Q: ... will treat urticaria in serum sickness
A: Diphenhydramine
3: Misc
4: Qbank 051-100.24

<!--T:45-->
C: Pharmacology
Q: alpha_1 blocker ... good in BPH and HT
A: Terazozin
3: Misc
4: Qbank 051-100.25

<!--T:46-->
C: Pharmacology
Q: Labetalol ... and ... ... ... indicated for ...
A: -Alpha and Beta receptor Blocker//-HTN
3: Misc
4: Qbank 051-100.25

<!--T:47-->
C: Pharmacology
Q: Cocain ... ... ...
A: bloking NE reuptake
3: Mechanism Of Action
4: Qbank 051-100.26

<!--T:48-->
C: Pharmacology
Q: Lidocaine, Mexiletine, Tocainide classified as class ... antiarrhythmic agents. ..., block ... channel and shorten ..., ... duration.
A: -1B//-V-Tach//-Na//-AP, ERP
3: Misc
4: Qbank 051-100.27

<!--T:49-->
C: Pharmacology
Q: Estmolol is a class ..., with ultrashort acting ... ... and ... properties.
A: -II//-Beta_1 blockage//-cardioselective
3: Misc
4: Qbank 051-100.27

<!--T:50-->
C: Pharmacology
Q: Diltiazem and Verapamil are ... channels blocker, and class ..., slow ... and ... conduction.
A: -Ca++//-IV//-SA and AV
3: Misc
4: Qbank 051-100.27

<!--T:51-->
C: Pharmacology
Q: Disopyramide and Procainamide are class ...
A: IA
3: Misc
4: Qbank 051-100.27

<!--T:52-->
C: Pharmacology
Q: Alcohol ... P450 in the ... of the liver.//Prove with elevated ... ... (...)
A: -enchances P450 in the SER//-GammaGlutamyl Transferase (GGT)
3: Misc
4: Qbank 051-100.28

<!--T:53-->
C: Pharmacology
Q: 5FU in DNA synthesis substiture ...,//in RNA - ...
A: DNA - THYMINE//RNA - Uracil
3: Misc
4: Qbank 051-100.29

<!--T:54-->
C: Pharmacology
Q: Clarithromycin ... hepatic enzymes => ... warfarin activity.
A: -inhibit hepatic enzymes//-enhances warfarin activity
3: Misc
4: Qbank 051-100.30

<!--T:55-->
C: Pharmacology
Q: ... inhibits biogenic amines reuptake at the presynaptic neuron.
A: TCA
3: CNS
4: Qbank 051-100.31

<!--T:56-->
C: Pharmacology
Q: Plasma concentration ...% = 1*t1/2
A: 50%
3: Misc
4: Qbank 051-100.32

<!--T:57-->
C: Pharmacology
Q: Plasma concentration ...% =  2*t1/2
A: 75%
3: Misc
4: Qbank 051-100.32

<!--T:58-->
C: Pharmacology
Q: Plasma concentration ...% = 3*t1/2
A: 87.5%
3: Misc
4: Qbank 051-100.32

<!--T:59-->
C: Pharmacology
Q: ... treat acne.
A: Tetracycline
3: Misc
4: Qbank 051-100.34

<!--T:60-->
C: Pharmacology
Q: Tetracycline precipitate with ... drug.
A: antiacid
3: Mics
4: Qbank 051-100.34

<!--T:61-->
C: Pharmacology
Q: Beta Blocker with intrinsic Sympat activity ... and ... are not indicated in ...
A: -ACEBUTALOL and PINDOLOL//-angina
3: Misc
4: Qbank 051-100.35

<!--T:62-->
C: Pharmacology
Q: Amphetamines induces ... release (... ...)
A: -DOPAMIN//-(indirect agonist)
3: CNS
4: Qbank 051-100.36

<!--T:63-->
C: Pharmacology
Q: Amphetamines induce ... ... wich lead to HTN (__)
A: -NE release//-(no CNS effect)
3: CNS
4: Qbank 051-100.36

<!--T:64-->
C: Pharmacology
Q: Bleomycin, Hydroxyurea, Mercaptopurine, Vincristine level ... antyemetic agents. (__)
A: -1//-(no emesis)
3: Misc
4: Qbank 051-100.37

<!--T:65-->
C: Pharmacology
Q: Pyridostigmine and Neostygmine inhibit AcetilCholineEsterase by ...
A: Carbamylation
3: Misc
4: Qbank 051-100.45

<!--T:66-->
C: Pharmacology
Q: Edrophonium short acting ... inhibitor of AcetilCholineEsterase.
A: competitive
3: Misc
4: Qbank 051-100.45

<!--T:67-->
C: Pharmacology
Q: Pralidoxime inhibit AcetilCholineEsterase by ...
A: Dephosphorylation
3: Misc
4: Qbank 051-100.45

<!--T:68-->
C: Pharmacology
Q: Pilocarpin and Betanechol are ... ... agonists.
A: direct muscarinic agonists
3: Misc
4: Qbank 051-100.45

<!--T:69-->
C: Pharmacology
Q: Curare ... ... blockers.
A: direct Nicotinic blockers
3: Misc
4: Qbank 051-100.45

<!--T:70-->
C: Pharmacology
Q: Echothiophate (and nerve gases) inhibit AcetilCholineEsterase by ...
A: Phosphorilation
3: Misc
4: Qbank 051-100.45

<!--T:71-->
C: Pharmacology
Q: ASA inhibit platelet aggregation by inhibiting production of ...
A: Tromboxane A2
3: Anticoagulants
4: Qbank 051-100.48

/KQB Pharmacology section.101-150

C: Pharmacology
Q: ... have active metabolites, phenobarbital and phenethylmalonamide (PEMA)
A: Primidone
3: CNS
4: Qbank 101-150.01

<!--T:73-->
C: Pharmacology
Q: ... is a benzodiazapine used for the treatment of absence, mioclonic, atypical absence, Lennox-Gastaut seizures.
A: Clonazepam
3: CNS
4: Qbank 101-150.01

<!--T:74-->
C: Pharmacology
Q: ... used for the treatment of partial seizures in adult and neuropathic pain in Diabetis
A: Gabapentin
3: CNS
4: Qbank 101-150.01

<!--T:75-->
C: Pharmacology
Q: ... is antiepileptic agent used for the treatment and prevention of tonic-clonic, focal, psychomotor seizures.
A: Phenytoin
3: CNS
4: Qbank 101-150.01

<!--T:76-->
C: Pharmacology
Q: amide-type local anasthetic (hepatic amidases) ...
A: double-i
3: Anasthetics
4: Qbank 101-150.02

<!--T:77-->
C: Pharmacology
Q: ester-type local anasthetic (plasma cholinestherase and hepatic esterases) ...
A: single-i
3: Anasthetics
4: Qbank 101-150.02

<!--T:78-->
C: Pharmacology
Q: interaction of ... containing food with MonoAmine  Oxidase Inhibitors (MAOIs)
A: thyramine
3: Drug Interaction
4: Qbank 101-150.03

<!--T:79-->
C: Pharmacology
Q: ... 5-HT3 receptor blockers - are antiemetic and antinauseant agents for cancer therapy
A: *setron
3: CNS
4: Qbank 101-150.05

<!--T:80-->
C: Pharmacology
Q: ... a mix of ligand gated ion channel receptor and G-protein coupled receptor. Increase ... rate.
A: -NMDA N-Methyl-D-Aspartat//-Firing
3: CNS
4: Qbank 101-150.06

<!--T:81-->
C: Pharmacology
Q: ... is a TriCyclic Antidepressant with significant ... effect.
A: -Amitriptylin//-anticholinergic
3: CNS
4: Qbank 101-150.07

<!--T:82-->
C: Pharmacology
Q: ... potentiate the effect of GABA, which result in antianxiety effect.
A: Benzodiazepines
3: CNS
4: Qbank 101-150.11

<!--T:83-->
C: Pharmacology
Q: Cardioselective B1 blockers ___
A: "A BEAM"//-Acebutalol,//-Betaxolol,//-Esmolol,//-Atenolol,//-Metoprolol.
3: Cardio
4: Qbank 101-150.13

<!--T:84-->
C: Pharmacology
Q: Labetolol blocks ..., ..., ...//Used in ... and ....
A: -Alpha.1, Beta.1, Beta.2//-HTN and pheochromocytoma
3: Cardio
4: Qbank 101-150.13

<!--T:85-->
C: Pharmacology
Q: ... blocks Beta.1 Beta.2 with long t1/2 (14/24hrs).
A: Nadolol
3: Cardio
4: Qbank 101-150.13

<!--T:86-->
C: Pharmacology
Q: Prazosin blocks ...//Used in ....
A: -Alpha.1//-HTN
3: Cardio
4: Qbank 101-150.13

<!--T:87-->
C: Pharmacology
Q: ... blocks Beta.1 Beta.2 in open angle glaucoma.
A: Timolol
3: Beta Blockers
4: Qbank 101-150.13

<!--T:88-->
C: Pharmacology
Q: ... atypical antidepressant with sedative side effect and priapism.
A: Trazodon
3: CNS
4: Qbank 101-150.14

<!--T:89-->
C: Pharmacology
Q: ... decrease conduction through AV node
A: Digoxin
3: Cardio
4: Qbank 101-150.15

<!--T:90-->
C: Pharmacology
Q: Ventricula tachycardia = ... ... complex
A: wide QRS compex
3: Cardio
4: Qbank 101-150.16

<!--T:91-->
C: Pharmacology
Q: ... is a Type ... antiarrhythmic agent with ... ... node automaticity, Increase ... ... and Decrease ... nodal conduction velocity.
A: -Propranolol//-Type II//-Decrease SA//-Increase AV ERP//-Decrease AV velocity
3: Beta Blocker
4: Qbank 101-150.16

<!--T:92-->
C: Pharmacology
Q: BENZO <- ...
A: FLUMAZENIL
3: Detox
4: Qbank 101-150.23

<!--T:93-->
C: Pharmacology
Q: ... <- ACETOMINOPHEN (Tylenol)
A: ACETYLCYSTEINE
3: Detox
4: Qbank 101-150.23

<!--T:94-->
C: Pharmacology
Q: Crohn's disease treat with ... (i.e. ...)//-... in Ulcerative colitis.
A: -corticosteroid (i.e. prednizone)//-suppositories in Ulcerative colitis.
3: GI
4: Qbank 101-150.24

<!--T:95-->
C: Pharmacology
Q: ... have high risk of seizures, contrindicated in bulimia or anorexia nervosa.
A: Bupropion
3: CNS
4: Qbank 101-150.25

<!--T:96-->
C: Pharmacology
Q: ... approved for anorexia nervosa and bulimia.
A: Fluoxetine
3: CNS
4: Qbank 101-150.25

<!--T:97-->
C: Pharmacology
Q: Aspirin inhibit ... .... The result is a ... ... ... related to ... ....
A: -secondary aggregation//-prolonged bleeding time//-platelet disFx
3: Coagulation
4: Qbank 101-150.29

<!--T:98-->
C: Pharmacology
Q: Indapamide, Metolazone are ... ....
A: thiazide diuretics
3: Classification
4: Qbank 101-150.32

<!--T:99-->
C: Pharmacology
Q: Hallmark of CLL is isolated ... ... ..%-..%.
A: -mature lymphocytosis//-75%-95%
3: Leukemia
4: Qbank 101-150.33

<!--T:100-->
C: Pharmacology
Q: Clorambucil, nitrogen mustard, ... ..., 
A: -alkalating DNA
3: Anticancer Drugs
4: Qbank 101-150.33

<!--T:101-->
C: Pharmacology
Q: Clorambucil used in ..., ... ... and ...
A: -CLL//-Ovarian CA//-Hodgkin's
3: Anticancer Drugs
4: Qbank 101-150.33

<!--T:102-->
C: Pharmacology
Q: Sumatriptan may cause ... ...
A: hypertensive crisis
3: CNS
4: Qbank 101-150.35

<!--T:103-->
C: Pharmacology
Q: Hypertensive emergency is elevated ... BP >...mmHg
A: -diastolic//>130 mmHg
3: HTN
4: Qbank 101-150.35

<!--T:104-->
C: Pharmacology
Q: ... can cause Wolf Parkinson White synd.
A: Digoxin
3: Cardio
4: Qbank 101-150.40

<!--T:105-->
C: Pharmacology
Q: Wolf Parkinson White synd is a specific ... ... make ... ... btw the atria and ventricule through the ... ....
A: -reentry tachycardia//-direct connection//-Kent bundels
3: Cardio
4: Qbank 101-150.40

<!--T:106-->
C: Pharmacology
Q: Wolf Parkinson White synd produce ... ... interval, but an early delta wave at the onset of ... ... ... ....
A: -short PR//-wide, slurred QRS complex
3: Cardio
4: Qbank 101-150.40

<!--T:107-->
C: Pharmacology
Q: Examples of reentrant tachycardia are ... ..., ... (... ... ...), ... ..., mcc ... (... ... ... synd)
A: -mcc WPWS (Wolf Parkinson White synd)//-atrial fib//-AVRT (AV reentrant tach)//-atrial flutter
3: Cardio
4: Qbank 101-150.40

<!--T:108-->
C: Pharmacology
Q: ... is primarily used for conversion of paroxismal supraventricular tach, including WPWS to normal sinus rhythm.
A: Adenosine
3: Cardio
4: Qbank 101-150.40

<!--T:109-->
C: Pharmacology
Q: ... used in the treatment of refractory ventricular tach and supraventricular tach, and prevention of ventr tach/fib
A: Amiodarone
3: Cardio
4: Qbank 101-150.40

<!--T:110-->
C: Pharmacology
Q: ... and ... are tetracyclines excreted by NONRENAL routes (intestinal lumen)
A: -Doxycycline//-Minocycline
3: Antibiotics
4: Qbank 101-150.42

<!--T:111-->
C: Pharmacology
Q: intravenous infusion = ... dose
A: maintenance
3: Pharmacokinetics
4: Qbank 101-150.46

<!--T:112-->
C: Pharmacology
Q: ... is a beta blocker can cause dyslipidemias in patiens.
A: Metoprolol
3: Beta Blockers
4: Qbank 101-150.47

<!--T:113-->
C: Pharmacology
Q: Guanfacin a centrally acting ... receptor ...
A: -alpha.2 agonist
3: CNS
4: Qbank 101-150.47

<!--T:114-->
C: Pharmacology
Q: Selegiline inhibit ... (... ... ...). Use in ...
A: -MAO-B (which methabolise dopamine)//-Parkinson
3: CNS
4: Qbank 101-150.49

<!--T:115-->
C: Pharmacology
Q: MAO-A methabolise ... and ...
A: -NE//-Serotonin
3: CNS
4: Qbank 101-150.49

<!--T:116-->
C: Pharmacology
Q: ... exacerbate CHF.
A: Verapamil
3: Ca++ channel blockers
4: Qbank 101-150.50

/KQB Pharmacology section.151-164

C: Pharmacology
Q: Loop diuretics works with Creatinin Clearence >...
A: > 10
3: Pharmacokinetics
4: Qbank 151-164.04

<!--T:118-->
C: Pharmacology
Q: Thiazide and K_sparing works with Creatinin Clearence >...
A: > 40
3: Pharmacokinetics
4: Qbank 151-164.04

<!--T:119-->
C: Pharmacology
Q: ACE inhibitor produce ..., mild ...
A: -HyperKalemia//-mild HypoNatremia
3: ACE inhibitors
4: Qbank 151-164.07

<!--T:120-->
C: Pharmacology
Q: Digoxin + ... and ... (...) lead to Premature Ventricular Contraction
A: hypoKalemia and hypoMagnesemic (diuretic)
3: Cardio
4: Qbank 151-164.08

<!--T:121-->
C: Pharmacology
Q: Doxepin is a ... with ... propertis (..., ... ...)
A: -TCA//-antiholinergic//-(tachycardia, dry mouth)
3: CNS
4: Qbank 151-164.

<!--T:122-->
C: Pharmacology
Q: Propyothiouracil primarily inhibit ... ..., (inhibition of conversion ...->... in ...)
A: -deiodination of thyroxine//-(inhibition of conversion T4->T3 in liver)
3: Anticancer drug
4: Qbank 151-164.12

<!--T:123-->
C: Pharmacology
Q: ... and ... => hemorrhagic cystitis <= prophilaxis with ...
A: -Ifosfamid and Cyclophosphamide//-prophilaxis with MESNA
3: Anticancer drugs
4: Qbank 151-164.13

USMLE Wiki

• Usmle Step1 | Usmle Step2 | Usmle Step3

• List of Cases > CSA&CS | Step3CCS

Popular: Usmle Step 3 CCS | Usmle Step 3 CCS cases part 2 - over 70 solved cases

Asters Notes > Asters Notes I | Asters Notes II | Asters Notes III

Other resources: Usmle Q Banks | Residency Wiki

List of patient cases